

CITATION REPORT

List of articles citing

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

DOI: 10.1002/pds.2082

Pharmacoepidemiology and Drug Safety, 2011, 20, 177-84.

Source: <https://exaly.com/paper-pdf/51451647/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
328	Rising off-label use of antipsychotics a concern in the US. 2011 , &NA;, 4		
327	Forum. 2011 , 25, 107-122		
326	Ten-year trends in quality of care and spending for depression: 1996 through 2005. 2011 , 68, 1218-26		25
325	Covert pharmaceutical promotion in free medical journals. 2011 , 183, 534-5		2
324	Out-of-hospital lingual dystonia resulting in airway obstruction. 2011 , 15, 537-40		1
323	Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. 2012 , 124, 154-67		64
322	Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009. 2012 , 63, 83-6		35
321	Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. 2012 , 200, 393-8		186
320	An update on lipid profile screening in second-generation antipsychotic users in the USA. 2012 , 7, 509-523		
319	Prenatal antipsychotic exposure and neuromotor performance during infancy. 2012 , 69, 787-94		68
318	Psychotropic marketing practices and problems: implications for DSM-5. 2012 , 200, 512-6		7
317	Association between the commercial characteristics of psychotropic drugs and their off-label use. 2012 , 50, 940-7		5
316	Psychopharmacology of Nonepisodic Irritability, Aggression, and Mood Swings in Children And Adolescents. 2012 , 47, 9-16		1
315	Off-label use of drugs and medical devices: a review of policy implications. 2012 , 91, 920-5		15
314	Off-label use of atypical antipsychotics: cause for concern?. 2012 , 26, 383-90		44
313	Off-label use of atypical antipsychotics in personality disorders. 2012 , 13, 1575-85		10
312	Search strategies to identify reports on "off-label" drug use in EMBASE. 2012 , 12, 190		10

311	Search strategies-identified reports on "off-label" drug use in MEDLINE. 2012 , 65, 827-34	9
310	Use of antipsychotic medication and suicidality--the Northern Finland Birth Cohort 1966. 2012 , 27, 476-85	5
309	Ten common questions (and their answers) about off-label drug use. 2012 , 87, 982-90	155
308	Off-label prescribing in older patients. 2012 , 29, 427-34	24
307	Off-label oft nicht wirksam. 2012 , 14, 26-26	
306	Treatment-emergent adverse events associated with atypical antipsychotics. 2012 , 13, 1587-98	47
305	Epidemiologic and clinical perspectives on antipsychotic treatment of children and adolescents. 2012 , 57, 715-6	6
304	Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 997-1004	2.6 28
303	The analysis of antipsychotic drugs in human matrices using LC-MS(/MS). 2012 , 4, 376-94	29
302	Are commonly used psychoactive medications associated with lower urinary tract symptoms?. 2012 , 68, 783-91	12
301	Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. 2013 , 43, 719-31	94
300	Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan. 2013 , 48, 1889-96	10
299	Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. 2013 , 15, 382	26
298	Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. 2013 , 36, 467-79	53
297	Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. 2013 , 16, 149-57	73
296	The use of clinical trials in comparative effectiveness research on mental health. 2013 , 66, S29-36	5
295	Use of antipsychotic medications in pediatric populations: what do the data say?. 2013 , 15, 426	56
294	Characteristics Associated With the Continuity of Atypical Antipsychotic Treatment Among Youth Discharged From Residential Treatment. 2013 , 30, 306-318	2

293	NHAMCS: does it hold up to scrutiny?. 2013 , 62, 549-551		17
292	Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. 2013 , 151, 573-581		34
291	Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. 2013 , 148, 99-104		30
290	Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. 2013 , 67, 170-80		12
289	Antipsychotics activate the TGF β pathway effector SMAD3. 2013 , 18, 347-57		13
288	Antipsychotic medications, glutamate, and cell death: a hidden, but common medication side effect?. 2013 , 80, 252-8		7
287	Psychotropic medication treatment of adolescents: results from the National Comorbidity Survey-Adolescent Supplement. 2013 , 52, 378-88		37
286	Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 794-801	2.6	33
285	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. 2013 , 18, 53-66		105
284	Farmaci off-label in endocrinologia clinica: rischi e aspetti regolatori. 2013 , 14, 64-70		
283	Antipsychotic Agents. 2013 , 31-88		
282	Diffusion of antipsychotics in the US And French markets, 1998-2008. 2013 , 64, 680-7		16
281	Generic atypical antipsychotic drugs in Belgium: their influence and implications. 2013 , 2, 551-61		11
280	Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. 2013 , 47, 74-87		149
279	Antipsychotic prescribing patterns, and the factors and outcomes associated with their use, among patients requiring prolonged mechanical ventilation in the long-term acute care hospital setting. 2013 , 47, 181-8		6
278	Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. 2013 , 10, e1001403		171
277	Disposable pipette extraction for the simultaneous determination of biperiden and three antipsychotic drugs in human urine by GC-nitrogen phosphorus detection. 2013 , 5, 21-9		12
276	Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. <i>BMJ Open</i> , 2013 , 3,	3	70

275	Evidence-based practice: a model for clinical application. 2013 , 19, 217-21		4
274	CriticalThinkRx May Reduce Psychiatric Prescribing to Foster Youth: Results From an Intervention Trial. 2013 , 23, 284-293		7
273	Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function. 2013 , 16, 1599-609		26
272	WITHDRAWN: Neural response to emotional stimuli associated with successful antidepressant treatment and behavioural activation. 2013 ,		
271	Use of quetiapine in child and adolescent populations - response to letter from Dr Lambe. 2013 , 47, 1084-5		1
270	Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. 2013 , 4, 139-150		6
269	Review of calls to an Australian teratogen information service regarding psychotropic medications over a 12-year period. 2013 , 53, 544-52		7
268	Polypharmacy reduction in youth in a residential treatment center leads to positive treatment outcomes and significant cost savings. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013 , 23, 620-7	2.9	7
267	Limitations and potential misinterpretation of the National Disease and Therapeutic Index. 2013 , 7, 34-44		1
266	Adverse clinical events among medicare beneficiaries using antipsychotic drugs: linking health insurance benefits and clinical needs. 2013 , 51, 614-21		6
265	Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function. 2013 , 8, e57308		40
264	Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future. 2012 , 3, 198		12
263	A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. 2014 , 9, e94788		63
262	Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. 2014 , 111, 25-34		47
261	Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013. 2014 , 31, 755-68		18
260	Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish. 2014 , 5, 153		56
259	Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. 2014 , 39, E1-2		2
258	Small geographic area variations in prescription drug use. 2014 , 134, 563-70		6

257	Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 87-94	2.6	5
256	Rapid determination of quetiapine in blood by gas chromatography-mass spectrometry. Application to post-mortem cases. 2014 , 34, 1104-8		9
255	Voltammetric and mathematical evidence for dual transport mediation of serotonin clearance in vivo. 2014 , 130, 351-9		36
254	Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2014 , 129, 328-42	6.5	15
253	Utilization of psychotropic drugs prescribed to persons with and without HIV infection: a Danish nationwide population-based cohort study. 2014 , 15, 458-69		10
252	Current Concepts Relative to the Appropriate Use of Antipsychotics in the Elderly. 2014 , 3, 253-258		
251	Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. 2014 , 12, 98		27
250	Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis. 2014 , 3, 133		5
249	Emergency department visits by adults for psychiatric medication adverse events. 2014 , 71, 1006-14		100
248	Prevalence and associations of quetiapine fumarate misuse among an Australian national city sample of people who regularly inject drugs. 2014 , 109, 295-302		4
247	Should off-label drugs be included as comparators in pharmacoeconomic studies?. 2014 , 32, 1035-7		1
246	Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014 , 24, 260-8	2.9	17
245	Antipsychotic use and the risk of rhabdomyolysis. 2014 , 27, 501-12		24
244	Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. 2014 , 14, 242		88
243	Prevalence of atypical antipsychotic use in psychiatric outpatients: comparison of women of childbearing age with men. 2014 , 17, 583-6		4
242	Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark. 2014 , 28, 963-73		11
241	Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. 2014 , 5, 100-9		53
240	The medicalisation of "ups and downs": the marketing of the new bipolar disorder. 2014 , 51, 581-98		22

239	Controversies in the use of second generation antipsychotics as sleep agent. 2014 , 79, 1-8		12
238	Risk of prostate cancer in patients with schizophrenia. 2014 , 55, 1639-42		10
237	Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. 2014 , 9, e105376		27
236	Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. <i>BMJ Open</i> , 2014 , 4, e005535	3	41
235	Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. 2015 , 14, 56-63		71
234	Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 583-91	2.6	20
233	Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN). 2015 , 9, 39-46		15
232	Pregnancy Outcomes Following In Utero Exposure to Second-Generation Antipsychotics: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Psychopharmacology</i> , 2015 , 35, 559-65	1.7	31
231	Mediators of First- Versus Second-generation Antipsychotic-related Mortality in Older Adults. 2015 , 26, 700-9		16
230	Solving Global Mental Health as a Delivery Problem. 544-574		3
229	Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. 2015 , 12, 135-40		28
228	Risk of Fetal Death after Treatment with Antipsychotic Medications during Pregnancy. 2015 , 10, e0132280		17
227	Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study. 2015 , 10, e0128312		41
226	Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment. 2015 , 21, 780-92		3
225	Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. 2015 , 18, pyv060		107
224	Antipsychotic use in pregnancy. 2015 , 16, 1335-45		31
223	Social and clinical descriptors of antipsychotic prescription. 2015 , 49, 45-62		5
222	Identifying psychiatric medications causing high numbers and rates of emergency department visits among US adults. 2015 , 18, e6		

221	Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population. 2015 , 11, 228-40	3
220	Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens. 2015 , 161, 452-7	22
219	Indications of atypical antipsychotics in the elderly. 2015 , 8, 5-7	16
218	Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. 2015 , 20, 407-21	10
217	Psychotropic Medications in Pregnancy. 2015 , 291-302	
216	Mandatory disclaimers on dietary supplements do not reliably communicate the intended issues. 2015 , 34, 438-46	22
215	Off-label paediatric drug use in an Indonesian community setting. 2015 , 40, 409-12	4
214	Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System. 2015 , 51, 685-94	14
213	Antipsychotic prescribing: do conflict of interest policies make a difference?. 2015 , 53, 338-45	8
212	Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. 2015 , 32, 305-14	36
211	A systematic review and meta-analysis of premature mortality in bipolar affective disorder. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 131, 417-25	6.5 185
210	Do antipsychotics increase diabetes risk in children and adolescents?. 2015 , 14, 219-41	21
209	Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study. 2016 , 4, E292-7	4
208	Factors Influencing the Use of Second-Generation Antipsychotics in Children with Psychosis. 2016 , 22, 948-57	3
207	Early Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System. 2016 , 17,	6
206	Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. 2016 , 11, e0152195	2
205	Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future Applications. 2016 , 11, e0163796	8
204	Trends in Off-Label Use of Second-Generation Antipsychotics in the Medicare Population From 2006 to 2012. 2016 , 67, 898-903	18

203	Evaluation and Management of Children With Acute Mental Health or Behavioral Problems. Part II: Recognition of Clinically Challenging Mental Health Related Conditions Presenting With Medical or Uncertain Symptoms. 2016 , 138,	10
202	Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. 2016 , 31, 249-58	41
201	Choosing Wisely: Wise Choices in Psychiatry. 2016 , 61, 700-704	3
200	The role of prescription medications in the association of self-reported sleep duration and obesity in U.S. adults, 2007-2012. 2016 , 24, 2210-6	10
199	Estimating 10-year cardiovascular disease risk in Asian patients with schizophrenia. 2016 , 43, 46-50	9
198	Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 26-34	2.6 14
197	Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study. 2016 , 51, 1623-1632	14
196	'Big data' in mental health research: current status and emerging possibilities. 2016 , 51, 1055-72	44
195	Antipsychotic prescribing patterns during and after critical illness: a prospective cohort study. 2016 , 20, 378	53
194	Mental health nurses' views about antipsychotic medication side effects. 2016 , 23, 369-77	3
193	Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. 2016 , 39, 925-43	19
192	Adverse event assessment methods in published trials of psychotropic drugs: Poor reporting and neglect of emerging safety concerns. 2016 , 28, 101-14	5
191	[Abuse Liability of Quetiapine (Xeroquel)]. 2015 ,	3
190	Prescribing according to diagnosis: how psychiatry is different. 2016 , 15, 224-225	11
189	Executive Summary: Evaluation and Management of Children With Acute Mental Health or Behavioral Problems. Part II: Recognition of Clinically Challenging Mental Health Related Conditions Presenting With Medical or Uncertain Symptoms. 2016 , 138,	3
188	Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. 2016 , 5, 16	1
187	Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review. 2016 , 31, 1083-91	49
186	Does the use of atypical antipsychotics as adjunctive therapy in depression result in cost savings? Comparing healthcare costs and utilization between second-line treatment options. 2016 , 25, 486-491	2

185	Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(□). 2016 , 39, 689-96	23
184	Quetiapine safety in older adults: a systematic literature review. 2016 , 41, 7-18	26
183	The geriatric mania asenapine study (GeMS). 2016 , 64, 111-4	12
182	Access to Psychosocial Services Prior to Starting Antipsychotic Treatment Among Medicaid-Insured Youth. 2016 , 55, 69-76.e3	22
181	Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics. 2016 , 128, 323-30	29
180	New users of antipsychotic medication: A population-based cohort study of occupational outcome measures in relation to antipsychotic on-label and off-label prescribing practices. 2016 , 31, 66-71	
179	Incident users of antipsychotics: who are they and how do they fare?. 2016 , 51, 505-12	4
178	Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats. 2016 , 30, 204-14	17
177	Antipsychotic medications and extreme weight gain in two health systems. 2016 , 10, 408-23	11
176	A Statewide Pediatric Psychiatry Consultation to Primary Care Program and the Care of Children with Trauma-related Concerns. 2016 , 43, 691-699	3
175	Continuation Rate of Atypical Antipsychotics After Discharge When Initiated in the Intensive Care Unit. 2017 , 30, 342-346	11
174	Prospective Assessment of Inpatient Boxed Warning Prescriber Adherence. 2017 , 13, 25-30	2
173	Classics in Chemical Neuroscience: Haloperidol. 2017 , 8, 444-453	34
172	Antipsychotics and the Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis of Observational Studies. 2017 , 18, 692-699	34
171	Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus. 2017 , 56, 642-651	27
170	Pattern of psychotropic medication use over two decades in Australian women. 2017 , 51, 1212-1219	5
169	Transformation of excess mortality in people with schizophrenia and bipolar disorder in Taiwan. <i>Psychological Medicine</i> , 2017 , 47, 2483-2493	6.9 9
168	Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States. 2017 , 68, 1112-1119	21

167	Extent and Risks of Antipsychotic Off-Label Use in Children and Adolescents in Germany Between 2004 and 2011. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017 , 27, 806-813	2.9	3
166	Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 642-656	2.6	17
165	Largest study to date shows overall use of antipsychotics in pregnancy does not appear to significantly increase the risk of congenital malformations. 2017 , 20, e7		
164	Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services. 2017 , 52, 561-578		24
163	Improved Metabolic and Psychiatric Outcomes with Discontinuation of Atypical Antipsychotics in Youth Hospitalized in a State Psychiatric Facility. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017 , 27, 897-907	2.9	4
162	International trends in antipsychotic use: A study in 16 countries, 2005-2014. 2017 , 27, 1064-1076		112
161	Increased Risk of Diabetes Among 6-24-Year-Olds Using Second Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017 , 27, 782-791	2.9	1
160	Prevalence and Risk Factors of Prolonged Corrected QT Interval Among Children and Adolescents Treated With Antipsychotic Medications: A Long-Term Follow-Up in a Real-World Population. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 78-83	1.7	14
159	Ethical Off-label Drug use: Need for a Rethink?. 2017 , 54, 447-450		4
158	Variation in use of antipsychotic medications in nursing homes in the United States: A systematic review. 2017 , 17, 32		34
157	Influence of socioeconomic status on antipsychotic prescriptions among youth in France. 2017 , 17, 82		4
156	Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011. 2017 , 26, 413-420		21
155	Comparison of pediatric atypical antipsychotic exposures reported to U.S. poison centers. 2017 , 55, 40-45		10
154	Plasma sphingolipids and depressive symptoms in coronary artery disease. 2017 , 7, e00836		13
153	Off-Label Prescribing and Polypharmacy: Minimizing the Risks. 2017 , 55, 17-22		
152	A National Survey of Graduate Education in Psychopharmacology: Advancing the Social Work Perspective on Psychiatric Medication. 2017 , 53, 424-434		6
151	Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?. 2017 , 23, 613-620		12
150	Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings. 2017 , 5,		5

149	Prenatal exposure to antipsychotic medication and use of primary health care system in childhood: a population-based cohort study in Denmark. 2017 , 9, 657-666		4
148	Social inequality, scientific inequality, and the future of mental illness. 2017 , 12, 10		7
147	National Patterns of Commonly Prescribed Psychotropic Medications to Young People. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018 , 28, 158-165	2.9	29
146	Improving Adherence to Atypical Antipsychotic Agent Screening Guidelines in Pediatric Patients: A Quality Improvement Project Within an Integrated Community Mental Health Setting. 2018 , 24, 352-359		8
145	The prescribing pattern of paliperidone in a pediatric population. 2018 , 28, 156-162		1
144	Acute Angle-closure Glaucoma Associated With Aripiprazole in the Setting of Plateau Iris Configuration. 2018 , 27, e40-e43		10
143	Prescribing Trends of Atypical Antipsychotic Drugs in an Outpatient Unit of a Child and Adolescent Clinic in Turkey. 2018 , 41, 23-27		3
142	Off-label prescription of psychiatric drugs by non-psychiatrist physicians in three general hospitals in Germany. 2018 , 17, 7		5
141	Patterns of Early Mental Health Diagnosis and Medication Treatment in a Medicaid-Insured Birth Cohort. 2018 , 172, 576-584		11
140	Schizophrenia: synthetic strategies and recent advances in drug design. 2018 , 9, 759-782		5
139	Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy. 2018 , 59, 125-134		8
138	Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors. 2018 , 14, 1569-1583		8
137	Association of Focused Medication Review With Optimization of Psychotropic Drug Prescribing: A Systematic Review and Meta-analysis. 2018 , 1, e183750		14
136	A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018 , 28, 582-605	2.9	27
135	Knowledge and attitudes of patients in primary care on off-label treatment. 2018 , 29, 181-192		2
134	Cannabis regulatory science: risk-benefit considerations for mental disorders. 2018 , 30, 183-202		24
133	Neuroleptic Prescribing and Monitoring Practices in Pediatric Inpatient Medical and Psychiatric Settings. 2018 , 8, 410-418		5
132	Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial. 2018 , 75, 1003-1011		52

131	Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA. 2018 , 14, 1545-1559		27
130	Blood Gene Expression Profile Predicts Response to Antipsychotics. 2018 , 11, 73		14
129	Cardiovascular Events Following Treatment Initiation with Atypical Antipsychotic Medications in Publicly Insured U.S. Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018 , 28, 445-453	2.9	4
128	Patterns and predictors of off-label prescription of psychiatric drugs. 2018 , 13, e0198363		25
127	Epigenetic Alterations Impact on Antipsychotic Treatment in Elderly Patients. 2018 , 5, 17-29		5
126	Treatment of depression, anxiety, and trauma-related disorders during the perinatal period: A systematic review. 2018 , 66, 136-148		56
125	Melatonin: Clinical Perspectives in Neurodegeneration. 2019 , 10, 480		87
124	Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs. 2019 , 39, 583-592		2
123	Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. 2019 , 28, 3303-3312		21
122	Mental Health Trends in Military Pediatrics. 2019 , 70, 657-664		4
121	Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder. 2019 , 2, e197850		12
120	Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia. 2019 , 25, 810-816		5
119	Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. 2019 , 19, 189		24
118	Pattern of use of clozapine in Spain. Variability and under-prescription. 2019 , 12, 151-162		
117	The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. 2019 , 35, 1205-1214		2
116	Use of Antipsychotic Drugs During Pregnancy. 2019 , 6, 17-31		3
115	Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. 2019 , 14, e0216044		15
114	Trajectories of antipsychotic use before and during pregnancy and associated maternal and birth characteristics. 2019 , 53, 1208-1221		4

113	A Research Agenda for the Assessment and Management of Acute Behavioral Changes in Elderly Emergency Department Patients. 2019 , 20, 393-402	5
112	Sex differences in gene expression related to antipsychotic induced weight gain. 2019 , 14, e0215477	8
111	Altered gene expression in antipsychotic-induced weight gain. 2019 , 5, 7	9
110	Epidemiology of the Use of Psychotropic Drugs in Pregnant and Nursing Women. 2019 , 3-16	
109	Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design. <i>BMJ Open</i> , 2019 , 9, e022984 ³	0
108	Neural circuitry and precision medicines for mental disorders: are they compatible?. <i>Psychological Medicine</i> , 2019 , 49, 1-8	6.9 20
107	Psychopharmacological prescribing practices in pregnancy for women with severe mental illness: A multicentre study. 2019 , 29, 57-65	6
106	Pattern of use of clozapine in Spain. Variability and under-prescription. 2019 , 12, 151-162	8
105	Changing prescribing patterns in an Irish community mental health service. 2020 , 37, 8-14	
104	Receipt of Promotional Payments at the Individual and Physician Network Level Associated with Higher Branded Antipsychotic Prescribing Rates. 2020 , 47, 73-85	2
103	Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles. 2020 , 29, 310-318	12
102	Toxin-Induced Subacute Encephalopathy. 2020 , 38, 799-824	1
101	Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. 2020 , 10, 2045125320937910	15
100	P.318 Safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. 2020 , 40, S184-S185	
99	Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics. 2020 , 13,	5
98	Cardiovascular risk screening of patients with serious mental illness or use of antipsychotics in family practice. 2020 , 21, 153	3
97	Psychotropic medications use and side effects of individuals with intellectual and developmental disabilities. 2020 , 64, 852	2
96	Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US. 2020 , 3, e2021476	139

95	Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane. 2020 , 81, 108399		6
94	Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns, healthcare costs and early cardio-metabolic occurrences from a large Italian database. 2020 , 76, 1301-1310		3
93	Antipsychotics Circa 2020: What are we thinking?. 2020 , 175, 108181		0
92	Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. 2020 , 77, 674-683		31
91	Off-label use of prescription analgesics among hospitalized children in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 474-481	2.6	3
90	RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings. <i>Journal of Clinical Psychopharmacology</i> , 2020 , 40, 259-268	1.7	12
89	Antipsychotic drug use in pregnancy: A multinational study from ten countries. 2020 , 220, 106-115		14
88	A cross-sectional study of psychotropic drug use in the elderly: Consuming patterns, risk factors and potentially inappropriate use. 2021 , 28, 88-93		0
87	Stroke Risk Among Elderly Users of Haloperidol and Typical Antipsychotics Versus Atypical Antipsychotics: A Real-World Study From a US Health Insurance Claims Database. 2021 , 29, 499-510		3
86	Systematic Review: System-wide Interventions to Monitor Pediatric Antipsychotic Prescribing and Promote Best Practice. 2021 , 60, 76-104.e7		10
85	References. 2021 , 499-522		
84	Interventions to Improve Metabolic Risk Screening Among Children and Adolescents on Antipsychotic Medication: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021 , 31, 63-72	2.9	2
83	Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. 2021 , 11, 59		7
82	The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children. <i>Frontiers in Psychiatry</i> , 2021 , 12, 623681	5	10
81	Olanzapine inhibits hepatic apolipoprotein A5 secretion inducing hypertriglyceridemia in schizophrenia patients and mice.		
80	Trends and characteristics of extra-medical use of quetiapine among people who regularly inject drugs in Australia, 2011-2018. 2021 , 221, 108636		1
79	Off-label uses of selective serotonin reuptake inhibitors (SSRIs). 2021 ,		6
78	Atypical antipsychotic olanzapine inhibits voltage-dependent K channels in coronary arterial smooth muscle cells. 2021 , 73, 1724-1733		0

77	Most Second-Generation Antipsychotic Prescriptions in Community Practice Are Neither FDA-Approved nor Within Prescribing Guideline Recommendations. 2021 , 26, 460-466	
76	Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics. 2021 , 20, 1207-1224	4
75	Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. 2021 ,	3
74	Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications.	1
73	Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems. 2021 , 17, 877-887	1
72	The evolving role and utility of off-label drug use in multiple myeloma.	
71	Trends in off-label use of antipsychotic medications among Texas Medicaid children and adolescents from 2013 to 2016. 2021 , 27, 1035-1045	2
70	Factors Associated With Off-Label Utilization of Second-Generation Antipsychotics Among Publicly Insured Adults. 2021 , 72, 1031-1039	
69	The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia. 2021 , 41, 853-863	0
68	Off-label antipsychotic use patterns among Texas Medicaid adults 2013-2016. 2021 , 10, 1045-1053	1
67	Cytoprotection by Melatonin: The Metabolic Syndrome as an Example. 2021 , 279-302	
66	Introduction: Pharmacological Treatments of Mental Disorders in Pregnancy. 2014 , 1-4	1
65	Off-label use of antipsychotics and associated factors in community living older adults. 2019 , 23, 158-165	5
64	Using Open Questions to Understand 650 People's Experiences With Antipsychotic Drugs. 2020 , 46, 896-904	16
63	Low dose morphine adjuvant therapy for enhanced efficacy of antipsychotic drug action: potential involvement of endogenous morphine in the pathophysiology of schizophrenia. 2012 , 18, HY23-6	8
62	Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 2013 , 8, e81208	39
61	Subjectively Experienced Benefits and Harms of Antipsychotics According to Users' Firsthand Accounts on the Internet. 2016 , 18, 196-217	1
60	Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices.	1

59	Can Declining Rates of Dementia Be Explained by the Increased and Widespread Use of Psychotropic Medications?. 2016 , 54, 25-9	3
58	Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior?. 2017 , 6, 12-15	11
57	Use of Antipsychotics: A Study from the French National Insurance Healthcare System Database. 2015 , 06, 411-419	3
56	Second generation antipsychotics & nocturnal enuresis in children. 2013 , 2, 370-374	0
55	Contemporary Pharmacotherapeutics and the Management of Aggressive Behavior in an Adolescent Animal Model of Maladaptive Aggression. 2020 , 18, 188-202	2
54	Hyperventilation and Respiratory Alkalosis After Olanzapine for Insomnia: A Case Report. 2021 , 15, e01535	0
53	Tardive Dyskinesia in Older Persons Taking Antipsychotics. 2021 , 17, 3127-3134	1
52	Prescription Drug and Pharmaceutical Policy. 2013 , 101-118	
51	Off-label use of atypical antipsychotic agents for treatment of insomnia. 2014 , 4, 65-72	3
50	New Research. 2017 , 22, 7-10,12	
49	[Antipsychotics: features of undesirable adverse reactions in elderly and senile age]. 2019 , 119, 105-117	1
48	Rates of new antipsychotic prescriptions and continuation at discharge from a medical unit in a community teaching hospital serving rural counties. 2019 , 9, 88-92	1
47	Prescription Pattern and Off-Label Use of Antipsychotics in a Middle Eastern Population. 2021 , 12, 753845	1
46	Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?. 2020 , 26, 1604-1611	1
45	Electron Transfer-Mediated Photodegradation of Phototoxic Antipsychotic Drug Quetiapine. 2021 , 6, 30834-30840	1
44	Pharmacology Update: Quetiapine-Has It Become a Novel Drug of Abuse?. 2020 , 31, 312-313	
43	Psychotropic Medication After Intensive Care Unit-Treated Pediatric Traumatic Brain Injury. 2020 , 112, 64-70	1
42	Pharmacological Treatment of Insomnia. 2015 , 40, 759-71	28

41	Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior. 2016 , 19, 45-59	10
40	Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures. 2016 , 19, 69-78	3
39	Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project. 2017 , 26, 98-103	5
38	Epigenetic Alterations Impact on Antipsychotic Treatment in Elderly Patients. 2018 , 5, 17-29	2
37	Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study. 2021 ,	0
36	Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study. 2021 , 8, 1071-1082	6
35	Antipsychotic prescribing patterns in Australia: a retrospective analysis.. 2022 , 22, 110	2
34	Care Pathways, Health Service Use Patterns and Opportunities for Justice Involvement Prevention Among Forensic Mental Health Clients.. 2022 , 7067437221076723	0
33	Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden.. 2022 ,	1
32	Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders: A National Birth Cohort Study.. 2022 ,	0
31	Antipsychotic prescription patterns and associated factors among the elderly with psychiatric illnesses.. 2022 ,	0
30	trends-in-the-utilization-of-psychotropic-drugs-in-serdang-hospital. 2021 , 7, 51-57	
29	Table_1.PDF. 2018 ,	
28	Table_2.DOCX. 2018 ,	
27	Table_3.DOCX. 2018 ,	
26	Table_4.DOCX. 2018 ,	
25	Table_5.DOCX. 2018 ,	
24	Antipsychotic drug waste: A potential corrosion inhibitor for mild steel in the oil and gas industry.. <i>Waste Management</i> , 2022 , 145, 38-47	8.6 0

23	Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.. <i>Journal of Clinical Psychopharmacology</i> , 2022 , 42, 238-246	1.7	1
22	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.. <i>Psychological Medicine</i> , 2022 , 1-19	6.9	2
21	Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient. <i>Frontiers in Psychiatry</i> , 2022 , 13,	5	
20	Patterns and predictors of oral antipsychotic prescribing in adult patients with schizophrenia. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022 , 6, 100148		0
19	Antipsychotic prescribing practices and patient, family member and healthcare professional perceptions of antipsychotic prescribing in acute care settings: a scoping review protocol. <i>BMJ Open</i> , 2022 , 12, e057585	3	0
18	Neonatal morbidity after fetal exposure to antipsychotics: a national register-based study. <i>BMJ Open</i> , 2022 , 12, e061328	3	1
17	Antipsychotics in the California Foster Care System: A 10-Year Analysis. <i>Journal of Child and Adolescent Psychopharmacology</i> ,	2.9	
16	Characteristics and predictors of off-label use of antipsychotics in general population sample. <i>Acta Psychiatrica Scandinavica</i> ,	6.5	1
15	A Study of Factors Causing Sleep State Misperception in Patients with Depression. <i>Nature and Science of Sleep</i> , Volume 14, 1273-1283	3.6	
14	Haloperidol and Other Antipsychotics Exposure before Endometrial Cancer Diagnosis: A Population-based Case-control Study. 2022 , 20, 526-535		
13	Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine. 13,		0
12	Pediatric Off-Label Antipsychotic Use for Attention-Deficit/Hyperactivity Disorder. 2022 ,		0
11	Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. 2022 , 21, 444-451		1
10	Trends in the utilization of psychotropic medications in China from 2018 to 2021. 13,		1
9	Impact of low-dose quetiapine-use on glycosylated haemoglobin, triglyceride and cholesterol levels.		0
8	Antipsychotics in the Management of Disruptive Behavior Disorders in Children and Adolescents: An Update and Critical Review. 2022 , 10, 2818		0
7	Roles of Pancreatic Islet Catecholamine Neurotransmitters in Glycemic Control and in Antipsychotic Drug-Induced Dysglycemia. 2023 , 72, 3-15		0
6	Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan. 2022 , 12, 204512532211396		0

- 5 Global occurrence and aquatic hazards of antipsychotics in sewage influents, effluent discharges and surface waters. **2023**, 121042 ○
- 4 Impact of removing prescription co-payments on the use of costly health services: a pragmatic randomised controlled trial. **2023**, 23, ○
- 3 Associations between mortality and exposure to psychotropic medication: A population-based cohort study for depressive disorders. 000486742211453 ○
- 2 Risk of Major Malformations Following First-Trimester Exposure to Olanzapine. **2023**, 43, 106-112 ○
- 1 Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries. **2023**, 18, e0284389 ○